eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
1/2008
vol. 3
 
Share:
Share:
more
 
 
abstract:

Review article
Pharmacodynamics, pharmacokinetics, drug interactions, toxicity and clinical efficacy of proton pump inhibitors – are the differences significant?

Paweł Petryszyn
,
Abdulhabib Annabhani
,
Leszek Paradowski

Przegląd Gastroenterologiczny 2008; 3 (1): 56–61
Online publish date: 2008/03/04
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Proton pump inhibitors (omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole) are commonly used for the treatment of gastro-oesophageal reflux disease and other acid-related gastrointestinal disorders as well. They all have a broadly similar mechanism of action and are metabolised in the liver via cytochrome P450 (CYP). They all have proved to be highly effective and generally safe. Different activation rates, binding sites within the H+/K+-ATPase and contribution of each CYP isoenzyme in their metabolism may produce differences in the potential for drug interactions and toxicity as well as onset and level of acid suppression. However, there is very little evidence to state that the differences in clinical efficacy of the five proton pump inhibitors are significant.
keywords:

proton pumps, pharmacokinetics, drug interactions, treatment outcome

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe